Gilead Research Grants: External-Sponsored Research - HIV RESONATE RFP
Gilead Sciences, Inc.
Funding Amount
Not stated
Deadline
Deadline not published
Grant Type
Foundation
Deadline history & next window
- Cycle
- Rolling — applications accepted year-round
- Tracked since
- April 2026
From the program guidelines: “Letter of Inquiry - Gilead will evaluate and rank LOIs received on a monthly basis until funds are exhausted.”
Overview
Gilead Research Grants support innovative, high-impact projects aimed at enhancing healthcare for vulnerable communities globally, particularly in HIV treatment. The organization invites research proposals that focus on improving outcomes across the HIV care cascade, with a funding pool of up to $4 million. Gilead prioritizes applications that demonstrate strong capabilities in delivering specific outcomes, emphasizing a commitment to supporting critical research in virology and other therapeutic areas.
NOTE:
Letter of Inquiry - Gilead will evaluate and rank LOIs received on a monthly basis until funds are exhausted. It is strongly recommended to submit earlier rather than later so that proposals can be evaluated while funding is still available. The listed Letter of Inquiry deadlines are the Submission deadlines for monthly LOI review.Full Proposal - Invite Only - A review of the LOIs will result in invitations for selected LOI applicants to submit a full application
What We Fund
We support community-informed, data-driven programs that strengthen healthcare infrastructures and provide education and financial support to the most vulnerable communities around the world. Our corporate giving programs focus support where the need is greatest and we prioritize applications that demonstrate a strong capability to deliver the specific outcomes the grant would support.
We welcome funding requests for innovative, high-impact projects that relate to at least one of our core therapeutic areas:
- HIV
- Liver disease
- Hepatitis CHepatitis BHepatitis DPrimary biliary cholangitisOncologyHematologySolid tumorsChronic Inflammatory Diseases
- Gilead Research Grants
Gilead funds externally-sponsored research, including community-based participatory research, and has a Research Scholars Program across our therapeutic areas of virology, oncology and inflammation.
We support research conducted by third parties on our products or within our therapeutic areas of interest. This research can provide valuable information regarding the safety, efficacy and tolerability of our products and supplements the comprehensive data generated in registration studies.
We are committed to generating and supporting critical, high-quality research that has an impact on clinical decision-making and patients’ lives. Our external-sponsored research program provides funding and/or study drug support for research efforts conducted by third parties on Gilead products or therapeutic areas.
We support two primary types of research, Investigator-Sponsored Research and Collaborative Research. We also support research where the study sponsor is a government organization, nonprofit organization or a pharmaceutical company.
Investigator-Sponsored Research (ISR) is initiated, designed, and led by independent researchers. For an ISR project, an investigator or institution outside of Gilead is the study sponsor. If the research concerns a Gilead product, the study must occur after regulatory approval of the product in the country where the study will be conducted. Gilead’s only involvement in an ISR project is solely providing funding and/or study drug support.Collaborative Research is similar to ISR where the study sponsor is an investigator or institution outside of Gilead. However, Gilead is involved in Collaborative Research beyond providing funding and/or study drug, such as involvement in study design, protocol development/review, conduct of study, providing data/biological samples, data/sample analysis and/or publication preparation/authorship.
Gilead supports the research efforts of academic institutions, clinical investigators, and research networks that focus on improving outcomes across the treatment care cascade for people with HIV.
Gilead is making a specific request for research study proposals in the disease area of HIV treatment, as further scientific data are needed on B/F/TAF and LEN to support medical management and decisions of clinicians and people with HIV.
Funding
Gilead plans to award up to $4,000,000 in funds for these research proposals, dependent upon availability of funds and receipt of meritorious applications. Gilead anticipates that up to 10 awards will be granted. Any proposal greater than $400,000 should be discussed with your Gilead Medical Scientist prior to submission. Proposed overhead costs should not exceed 30% of total budget.
Focus Areas & Funding Uses
Fields of Work
- HIV/AIDS
- Science research
- Nonprofits
- Health disparities
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Gilead Africa Grants
Gilead Sciences, Inc.
Amount
Varies
Deadline
Deadline not published
Gilead Australia Grants
Gilead Sciences, Inc.
Amount
Varies
Deadline
Deadline not published
Gilead Asia Grants
Gilead Sciences, Inc.
Amount
Varies
Deadline
Deadline not published
Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
National Institutes of Health
Amount
$7,000,000 total
Deadline
June 20, 2029
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 5, 2027
Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 CT Not Allowed)
National Institutes of Health
Amount
$1,000,000 total
Deadline
October 20, 2028
Ready to apply for Gilead Research Grants: External-Sponsored Research - HIV RESONATE RFP?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Gilead Research Grants: External-Sponsored Research - HIV RESONATE RFP. Now let's win it.